{"public_id":"cl_a295e1ebe62443662f28a537132fece6","status":"active","superseded_by_public_id":null,"corpus_id":56877356,"text":"The observed findings are consistent with a recommended azathioprine dose of 2-3 mg/kg/day.","confidence":0.84,"paper":{"corpus_id":56877356,"title":"Measuring Clinical Efficacy of Azathioprine in Myasthenia Gravis with Mean Corpuscular Volume (P5.036)","url":"https://sah.borca.ai/papers/56877356"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.84,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_a498876da942b11e9e60476a9baae401","name":"myasthenia gravis","description":"An autoimmune neuromuscular disorder characterized by fluctuating muscle weakness.","types":["condition"],"url":"https://sah.borca.ai/concepts/co_a498876da942b11e9e60476a9baae401"},{"public_id":"co_b6e1b546a4c55597b30590f1f9b9fa8b","name":"recommended azathioprine dose","description":"The cited target dosing range for azathioprine in myasthenia gravis.","types":["dose recommendation"],"url":"https://sah.borca.ai/concepts/co_b6e1b546a4c55597b30590f1f9b9fa8b"},{"public_id":"co_d526b7412e0255a2e89aa87c22057d5e","name":"azathioprine","description":"An immunosuppressive steroid-sparing medication used in the management of myasthenia gravis.","types":["drug"],"url":"https://sah.borca.ai/concepts/co_d526b7412e0255a2e89aa87c22057d5e"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_a295e1ebe62443662f28a537132fece6"}